Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.51 |
| ▸ | GABRD | O14764 | 4/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.51 |
| ▸ | GABRE | P78334 | 4/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862484 | 0.91 | GAA (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17675678 | 0.84 | JAK2 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL463343 | 0.81 | IDO1 (0.50) | PRKCIKCNH2JAK2IDO1CYP11B2 | |
| SCHEMBL1865660 | 0.79 | DDB1 (0.53) | PRKCIJAK2JAK1HSD17B10GAA | |
| SCHEMBL4671267 | 0.79 | IRAK4 (0.51) | PRKCIJAK2JAK1HSD17B10GAA | |
| SCHEMBL4752964 | 0.79 | CCR3 (0.51) | PRKCIJAK2JAK1HSD17B10GAA | |
| SCHEMBL30610095 | 0.79 | IRAK4 (0.51) | PRKCIJAK2JAK1HSD17B10GAA | |
| Piperazine SCHEMBL28324587 | 0.78 | IRAK4 (0.50) | PRKCIJAK2JAK1IDO1HSD17B10 | |
| SCHEMBL3290233 | 0.77 | DRD2 (0.57) | PRKCIJAK2JAK1SLC6A4ALDH1A1 | |
| SCHEMBL2850424 | 0.76 | LMNA (0.53) | PRKCIJAK2JAK1IDO1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | GABRP 657/4885GABRD 671/4885GABRA1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.